Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics

Eli Lilly is acquiring Verve Therapeutics for $1.3 billion, a 113% premium over Verve's 30-day average, sending Verve's stock up 80%. The acquisition provides Lilly with Verve’s gene-editing technology targeting PCSK9 for cholesterol reduction, diversifying Lilly's portfolio beyond diabetes and obesity and expanding its presence in cardiovascular therapeutics. While Lilly's valuation remains below its 3-year average P/E, key risks include market volatility, valuation sensitivity, and portfolio concentration in obesity drugs; however, the Verve acquisition reinforces Lilly’s position as an attractive investment.

Analysis

Eli Lilly's acquisition of Verve Therapeutics for $1.3 billion, representing a significant 113% premium over Verve's 30-day volume-weighted average price, marks a strategic expansion into the cardiovascular genetic medicine sector. This move, which caused Verve's stock to surge by 80% on June 17, 2025, aligns with Eli Lilly's objective to diversify its portfolio beyond its primary diabetes and obesity treatments. Verve's innovative gene-editing technology, focused on deactivating the PCSK9 gene to lower high cholesterol, offers Lilly a foothold in a high-impact therapeutic area and enhances its genetic medicine capabilities. Despite the substantial premium paid for Verve, Eli Lilly's valuation remains somewhat grounded relative to its recent history; the company trades at 57 times trailing adjusted earnings of $13.76 per share, which is below its three-year average P/E ratio of 66 times. However, several risks persist: Eli Lilly has shown vulnerability during broader market downturns, its elevated multiple makes it sensitive to any disappointments in execution or negative shifts in market sentiment, and there is a notable concentration risk due to its reliance on the obesity drug market. The Verve acquisition is viewed as a positive step in addressing some of these concerns by expanding into new high-potential areas, thereby reinforcing Eli Lilly's investment appeal.

Key Decisions for Investors

• Investors should recognize the Verve Therapeutics acquisition as a strategic enhancement to Eli Lilly's long-term growth profile through diversification into cardiovascular genetic medicine, despite the considerable acquisition premium.
• Monitor Eli Lilly's progress in integrating Verve's gene-editing technology and its ability to deliver on the potential of this new therapeutic area to validate the investment.
• While Eli Lilly's current P/E of 57 is below its three-year average, its elevated nature warrants caution regarding sensitivity to execution performance and market sentiment, particularly concerning its core obesity drug franchise.
• Consider the identified risks, including Eli Lilly's historical market volatility, valuation sensitivity, and existing portfolio concentration, when evaluating positions, even as this acquisition aims to mitigate some concentration risk.